Acute Graft-versus-Host Disease - Biologic Process, Prevention, and Therapy

Overview

Journal N Engl J Med

Specialty General Medicine

Date 2017 Nov 25

PMID 29171820

Citations 564

Authors

Robert Zeiser

Bruce R Blazar

Affiliations

Soon will be listed here.

Citing Articles

Whole-Blood Longitudinal Molecular Profiling Maps the Road of Graft Versus Host Disease (GVHD).

Bar M, El Anbari M, Rinchai D, Toufiq M, Kizhakayil D, Manjunath H Cancers (Basel). 2025; 17(5).

PMID: 40075650 PMC: 11899482. DOI: 10.3390/cancers17050802.

Macrophages in graft-versus-host disease (GVHD): dual roles as therapeutic tools and targets.

Raoufi A, Soleimani Samarkhazan H, Nouri S, Khaksari M, Abbasi Sourki P, Sargazi Aval O Clin Exp Med. 2025; 25(1):73.

PMID: 40048037 PMC: 11885342. DOI: 10.1007/s10238-025-01588-0.

Free fatty acid receptor-4 regulates T-cell-mediated allogeneic reaction through activating an aryl hydrocarbon receptor pathway.

Duah M, Zheng F, Shen J, Xu Y, Cao S, Yan Z Acta Pharm Sin B. 2025; 15(1):224-238.

PMID: 40041898 PMC: 11873605. DOI: 10.1016/j.apsb.2024.12.011.

NFAT single-deficient murine T cells reduce the risk of aGvHD while controlling cytomegalovirus infection.

Hundhausen N, Majumder S, Xiao Y, Haeusl S, Goehler H, Seal R iScience. 2025; 28(2):111937.

PMID: 40028277 PMC: 11872454. DOI: 10.1016/j.isci.2025.111937.

Improving bench-to-bedside translation for acute graft-versus-host disease models.

McDaniel Mims B, Furr K, Enriquez J, Grisham M Dis Model Mech. 2025; 18(2).

PMID: 40019007 PMC: 11892683. DOI: 10.1242/dmm.052084.

References

Saha A, OConnor R, Thangavelu G, Lovitch S, Dandamudi D, Wilson C . Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest. 2016; 126(7):2642-60. PMC: 4922691. DOI: 10.1172/JCI85796. View

Toubai T, Hou G, Mathewson N, Liu C, Wang Y, Oravecz-Wilson K . Siglec-G-CD24 axis controls the severity of graft-versus-host disease in mice. Blood. 2014; 123(22):3512-23. PMC: 4041170. DOI: 10.1182/blood-2013-12-545335. View

Jankovic D, Ganesan J, Bscheider M, Stickel N, Weber F, Guarda G . The Nlrp3 inflammasome regulates acute graft-versus-host disease. J Exp Med. 2013; 210(10):1899-910. PMC: 3782050. DOI: 10.1084/jem.20130084. View

Furlan S, Watkins B, Tkachev V, Flynn R, Cooley S, Ramakrishnan S . Transcriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention. Sci Transl Med. 2015; 7(315):315ra191. PMC: 4876606. DOI: 10.1126/scitranslmed.aad3231. View

Jasperson L, Bucher C, Panoskaltsis-Mortari A, Mellor A, Munn D, Blazar B . Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood. 2009; 114(24):5062-70. PMC: 2788979. DOI: 10.1182/blood-2009-06-227587. View

Uryu H, Hashimoto D, Kato K, Hayase E, Matsuoka S, Ogasawara R . α-Mannan induces Th17-mediated pulmonary graft-versus-host disease in mice. Blood. 2015; 125(19):3014-23. DOI: 10.1182/blood-2014-12-615781. View

Luznik L, Bolanos-Meade J, Zahurak M, Chen A, Smith B, Brodsky R . High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood. 2010; 115(16):3224-30. PMC: 2858487. DOI: 10.1182/blood-2009-11-251595. View

Chen Y, Efebera Y, Johnston L, Ball E, Avigan D, Lekakis L . Increased Foxp3Helios Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells. Biol Blood Marrow Transplant. 2017; 23(4):625-634. PMC: 5437739. DOI: 10.1016/j.bbmt.2017.01.069. View

Zeiser R, Blazar B . Preclinical models of acute and chronic graft-versus-host disease: how predictive are they for a successful clinical translation?. Blood. 2016; 127(25):3117-26. PMC: 4920018. DOI: 10.1182/blood-2016-02-699082. View

10.

Graubert T, DiPersio J, Russell J, Ley T . Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J Clin Invest. 1997; 100(4):904-11. PMC: 508263. DOI: 10.1172/JCI119606. View

11.

Blazar B, Taylor P, Snover D, Sehgal S, Vallera D . Murine recipients of fully mismatched donor marrow are protected from lethal graft-versus-host disease by the in vivo administration of rapamycin but develop an autoimmune-like syndrome. J Immunol. 1993; 151(10):5726-41. View

12.

Giroux M, Delisle J, Gauthier S, Heinonen K, Hinsinger J, Houde B . SMAD3 prevents graft-versus-host disease by restraining Th1 differentiation and granulocyte-mediated tissue damage. Blood. 2010; 117(5):1734-44. DOI: 10.1182/blood-2010-05-287649. View

13.

Wilhelm K, Ganesan J, Muller T, Durr C, Grimm M, Beilhack A . Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med. 2010; 16(12):1434-8. DOI: 10.1038/nm.2242. View

14.

Jagasia M, Arora M, Flowers M, Chao N, McCarthy P, Cutler C . Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2011; 119(1):296-307. PMC: 3251233. DOI: 10.1182/blood-2011-06-364265. View

15.

Bacchetta R, Lucarelli B, Sartirana C, Gregori S, Lupo Stanghellini M, Miqueu P . Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells. Front Immunol. 2014; 5:16. PMC: 3907718. DOI: 10.3389/fimmu.2014.00016. View

16.

Kroger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M . Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease. N Engl J Med. 2016; 374(1):43-53. DOI: 10.1056/NEJMoa1506002. View

17.

Lindemans C, Calafiore M, Mertelsmann A, OConnor M, Dudakov J, Jenq R . Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration. Nature. 2015; 528(7583):560-564. PMC: 4720437. DOI: 10.1038/nature16460. View

18.

Harris A, Young R, Devine S, Hogan W, Ayuk F, Bunworasate U . International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium. Biol Blood Marrow Transplant. 2015; 22(1):4-10. PMC: 4706482. DOI: 10.1016/j.bbmt.2015.09.001. View

19.

Iyengar S, Zhan C, Lu J, Korngold R, Schwartz D . Treatment with a rho kinase inhibitor improves survival from graft-versus-host disease in mice after MHC-haploidentical hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014; 20(8):1104-11. PMC: 4103026. DOI: 10.1016/j.bbmt.2014.04.029. View

20.

Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder S . Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia. 2015; 29(10):2062-8. PMC: 4854652. DOI: 10.1038/leu.2015.212. View